Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,481 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Dupilumab in patients with chronic spontaneous urticaria (LIBERTY-CSU CUPID): Two randomized, double-blind, placebo-controlled, phase 3 trials.
Maurer M, Casale TB, Saini SS, Ben-Shoshan M, Giménez-Arnau AM, Bernstein JA, Yagami A, Stjepanovic A, Radin A, Staudinger HW, Patel N, Amin N, Akinlade B, Fan C, Bauer D, Yancopoulos GD, Patel K, Mannent LP, Laws E. Maurer M, et al. Among authors: amin n. J Allergy Clin Immunol. 2024 Feb 29:S0091-6749(24)00196-9. doi: 10.1016/j.jaci.2024.01.028. Online ahead of print. J Allergy Clin Immunol. 2024. PMID: 38431226 Free article.
Efficacy and safety of dupilumab in patients with uncontrolled severe chronic rhinosinusitis with nasal polyps and a clinical diagnosis of NSAID-ERD: Results from two randomized placebo-controlled phase 3 trials.
Mullol J, Laidlaw TM, Bachert C, Mannent LP, Canonica GW, Han JK, Maspero JF, Picado C, Daizadeh N, Ortiz B, Li Y, Ruddy M, Laws E, Amin N. Mullol J, et al. Among authors: amin n. Allergy. 2022 Apr;77(4):1231-1244. doi: 10.1111/all.15067. Epub 2021 Oct 1. Allergy. 2022. PMID: 34459002 Free PMC article.
Dupilumab in patients with prurigo nodularis: two randomized, double-blind, placebo-controlled phase 3 trials.
Yosipovitch G, Mollanazar N, Ständer S, Kwatra SG, Kim BS, Laws E, Mannent LP, Amin N, Akinlade B, Staudinger HW, Patel N, Yancopoulos GD, Weinreich DM, Wang S, Shi G, Bansal A, O'Malley JT. Yosipovitch G, et al. Among authors: amin n. Nat Med. 2023 May;29(5):1180-1190. doi: 10.1038/s41591-023-02320-9. Epub 2023 May 4. Nat Med. 2023. PMID: 37142763 Free PMC article. Clinical Trial.
Dupilumab improves patient-reported outcomes in patients with chronic rhinosinusitis with nasal polyps and comorbid asthma.
Bachert C, Hellings PW, Mullol J, Naclerio RM, Chao J, Amin N, Grabher A, Swanson BN, Hamilton JD, Guillonneau S, Taniou C, Zhang D, Pirozzi G, Graham NMH, Staudinger H, Mannent LP, Khan A. Bachert C, et al. Among authors: amin n. J Allergy Clin Immunol Pract. 2019 Sep-Oct;7(7):2447-2449.e2. doi: 10.1016/j.jaip.2019.03.023. Epub 2019 Mar 27. J Allergy Clin Immunol Pract. 2019. PMID: 30928658 Free article. Clinical Trial. No abstract available.
Dupilumab improves health-related quality of life in patients with chronic rhinosinusitis with nasal polyposis.
Bachert C, Hellings PW, Mullol J, Hamilos DL, Gevaert P, Naclerio RM, Joish VN, Chao J, Mannent LP, Amin N, Abbe A, Taniou C, Fan C, Pirozzi G, Graham NMH, Mahajan P, Staudinger H, Khan A. Bachert C, et al. Among authors: amin n. Allergy. 2020 Jan;75(1):148-157. doi: 10.1111/all.13984. Epub 2019 Oct 23. Allergy. 2020. PMID: 31306495 Clinical Trial.
Dupilumab Efficacy in Uncontrolled, Moderate-to-Severe Asthma with Self-Reported Chronic Rhinosinusitis.
Maspero JF, Katelaris CH, Busse WW, Castro M, Corren J, Chipps BE, Peters AT, Pavord ID, Ford LB, Sher L, Rabe KF, Rice MS, Rowe P, Lu Y, Harel S, Jagerschmidt A, Khan AH, Kamat S, Pirozzi G, Amin N, Ruddy M, Graham NMH, Mannent LP, Teper A. Maspero JF, et al. Among authors: amin n. J Allergy Clin Immunol Pract. 2020 Feb;8(2):527-539.e9. doi: 10.1016/j.jaip.2019.07.016. Epub 2019 Jul 24. J Allergy Clin Immunol Pract. 2020. PMID: 31351189 Free article. Clinical Trial.
Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials.
Bachert C, Han JK, Desrosiers M, Hellings PW, Amin N, Lee SE, Mullol J, Greos LS, Bosso JV, Laidlaw TM, Cervin AU, Maspero JF, Hopkins C, Olze H, Canonica GW, Paggiaro P, Cho SH, Fokkens WJ, Fujieda S, Zhang M, Lu X, Fan C, Draikiwicz S, Kamat SA, Khan A, Pirozzi G, Patel N, Graham NMH, Ruddy M, Staudinger H, Weinreich D, Stahl N, Yancopoulos GD, Mannent LP. Bachert C, et al. Among authors: amin n. Lancet. 2019 Nov 2;394(10209):1638-1650. doi: 10.1016/S0140-6736(19)31881-1. Epub 2019 Sep 19. Lancet. 2019. PMID: 31543428 Clinical Trial.
Chronic Rhinosinusitis with Nasal Polyps and Asthma.
Laidlaw TM, Mullol J, Woessner KM, Amin N, Mannent LP. Laidlaw TM, et al. Among authors: amin n. J Allergy Clin Immunol Pract. 2021 Mar;9(3):1133-1141. doi: 10.1016/j.jaip.2020.09.063. Epub 2020 Oct 13. J Allergy Clin Immunol Pract. 2021. PMID: 33065369 Free article.
Dupilumab improves upper and lower airway disease control in chronic rhinosinusitis with nasal polyps and asthma.
Laidlaw TM, Bachert C, Amin N, Desrosiers M, Hellings PW, Mullol J, Maspero JF, Gevaert P, Zhang M, Mao X, Khan AH, Kamat S, Patel N, Graham NMH, Ruddy M, Staudinger H, Mannent LP. Laidlaw TM, et al. Among authors: amin n. Ann Allergy Asthma Immunol. 2021 May;126(5):584-592.e1. doi: 10.1016/j.anai.2021.01.012. Epub 2021 Jan 16. Ann Allergy Asthma Immunol. 2021. PMID: 33465455 Free article. Clinical Trial.
1,481 results